EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based
biopharmaceutical company focused on the global development and
commercialization of biosimilar monoclonal antibodies, announced that
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will
serve on its board of directors. The board, which was reconstituted
today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ:
ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J.
Kevin Buchi and Daotian Fu.
"We are very pleased to have Mark, Julie, and Bill on our board," said
Amit Munshi, president and chief executive officer of EPIRUS. "Their
expertise and guidance will be invaluable in our quest to build a
Dr. Corrigan will serve as the chairman of the EPIRUS board. Dr.
Corrigan served as a director and was the president and chief executive
officer of Zalicus from 2010 to 2014. Dr. Corrigan joined the specialty
pharmaceutical company Sepracor Inc. in 2003 and served as their
executive vice president of research and development until December
2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with
Pharmacia & Upjohn Inc., most recently as group vice president of global
clinical research and experimental medicine. Before he entered the
pharmaceutical industry, Dr. Corrigan spent five years in academic
research at the University of North Carolina School of Medicine,
focusing on psychoneuroendocrinology. Dr. Corrigan also serves on the
board of directors of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST), and
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR). Dr. Corrigan holds a B.A.
and an M.D. from the University of Virginia and received specialty
training in psychiatry at Maine Medical Center and Cornell University.
Ms. McHugh will serve on the EPIRUS board as a director and member of
the Audit and Compensation Committees. Ms. McHugh recently served as
chief operating officer for Endo Health Solutions, Inc., where she was
responsible for the specialty pharmaceutical and generic drug
businesses. Prior to joining Endo, Ms. McHugh was the chief executive
officer of Nora Therapeutics, Inc., a venture capital backed company
developing novel therapies for the treatment of infertility disorders.
Ms. McHugh also served as company group chairman for Johnson & Johnson's
worldwide virology business unit from 2006 to 2008, and she was
previously president of Centocor, Inc., a J&J subsidiary. While at J&J,
Ms. McHugh oversaw the development and launches of several products,
including Remicade® (infliximab), Prezista®
(darunavir) and Intelence® (etravirine). She currently serves
on the board of visitors for the Smeal College of Business of the
Pennsylvania State University and the board of directors for Ironwood
Pharmaceuticals, Inc. (NASDAQ:IRWD), Trevena, Inc. (NASDAQ:TRVN), and
The New Xellia Group, a privately held company. She previously served on
the board of directors for ViroPharma Inc., the Biotechnology Industry
Organization (BIO), the Pennsylvania Biotechnology Association and the
New England Healthcare Institute (NEHI). Ms. McHugh received her masters
of business administration degree from St. Joseph's University and her
Bachelor of Science degree from Pennsylvania State University.
Dr. Hunter will serve on the EPIRUS board as a director and member of
the Audit and Governance Committees. He is the president and chief
executive officer of Cardiome Pharma Corp., a position he has held since
July of 2012. He has also served as a director of Cardiome since 2007.
Cardiome is a cardiovascular drug development company based in Vancouver
(NASDAQ:CRME). Prior to Cardiome, Dr. Hunter co-founded Angiotech
Pharmaceuticals in 1992 and became its chief executive officer in 1997.
He led Angiotech through 3 rounds of private equity financing, an IPO
and listing on the Toronto Stock Exchange and NASDAQ, over $1B in equity
and debt financings, a debt restructuring and 8 acquisitions. During
that time, Angiotech became a profitable and diversified healthcare
company with over 1,400 employees, several thousand commercially
available products, 12 facilities in 5 countries and annual revenues
exceeding $250M. Dr. Hunter also serves a director Union Medtech, and he
previously served as a director of Zalicus. Dr. Hunter holds a B.Sc.
from McGill University, and an M.Sc. and M.D. from the University of
British Columbia. He served as a practicing physician in British
Columbia for 5 years, and he has over 200 patents and patent
applications to his name.
EPIRUS is building a global biosimilar enterprise to improve patient
access to important medicines. The company's strategy for commercial
success relies on targeted approaches for diverse global markets.
For emerging markets with accessible regulatory frameworks for
biosimilars, EPIRUS develops partnerships with local companies to
accelerate regulatory approval and commercialize its products.
For high-growth global markets where local manufacturing confers
strategic and operational advantages, EPIRUS intends to use its SCALE™
platform to deliver an "In Market, For Market™" manufacturing solution
with local partners.
For large markets with an established biosimilar regulatory framework,
such as Europe, EPIRUS plans to commercialize its products using a
combination of direct sales and local distributors.
More information about EPIRUS can be found at www.epirusbiopharma.com
Remicade®, Prezista® and Intelence® are
all registered trademarks of Johnson and Johnson (www.jnj.com)
Source: EPIRUS Biopharmaceuticals, Inc.